11. November 2009 04:02
As the debate over health care reform dominates the media and political arena, a new American Lung Association report finds that states aren't doing enough to help smokers quit - and policymakers must fix this in the health care reform process.
[More]
3. November 2009 05:01
In a comparison of five different smoking cessation medications, a nicotine patch plus a nicotine lozenge appears most effective at helping smokers quit, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
[More]
30. October 2009 06:09
A Monash University physiologist, whose research into weight management, obesity and diabetes has led to significant medical breakthroughs and drug design, has been awarded one of the nation's top research honours.
[More]
28. October 2009 05:42
22nd Century Limited, LLC is pleased to announce that it is continuing development of a very low nicotine cigarette for use in smoking cessation. Clinical trial results demonstrate that these cigarettes, also referred to as ‘nicotine-free’ and ‘denicotinized,’ may be more effective for quitting than FDA-approved therapies.
[More]
07d01c75-4fb4-4e52-8140-06a7524ff8db|0|.0
Posted in: Miscellaneous News
Tags: Abstinence, Biotechnology, Bupropion, Cancer, Dentistry, New Drug Application, Nicotine, Smoking, Smoking Cessation, Tobacco, Zyban
28. October 2009 05:07
Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.
[More]
c5297634-1be0-428b-8cd3-35980dd45949|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Blood Pressure, Bupropion, Constipation, Depression, Diabetes, Headache, Nausea, Nervous System, New Drug Application, Obesity, Weight Loss
27. October 2009 08:11
Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.
[More]
26. October 2009 01:57
Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.
[More]
f84b3031-e95d-484c-8328-88b51922d31c|1|5.0
Posted in: Drug Trial News | Medical Condition News
Tags: Blood Pressure, Bupropion, Cardiovascular Disease, Constipation, Depression, Diabetes, Headache, Nausea, Nervous System, New Drug Application, Obesity, Type 2 Diabetes, Weight Loss
1. October 2009 09:22
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
[More]
e6925b29-61a5-4214-8f8e-05e954c67aae|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anxiety, Blood Pressure, Bupropion, Cognitive Function, Depression, Diet, Dyslipidemia, Exercise, Headache, Insomnia, Insulin, Nausea, Nervous System, New Drug Application, Nutrition, Obesity, Urticaria, Weight Loss
11. September 2009 08:23
Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research.
[More]
f4f2fb8e-6285-46d9-8e8b-4076fef44912|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antidepressant, Biomarker, Brain, Bupropion, Depression, Hospital, Mental Health, Neuroscience, Psychiatry, Serotonin, Venlafaxine
11. September 2009 03:55
Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.
[More]
b1ff29af-68b6-43b4-a3f9-e1f167c68d1e|0|.0
Posted in: Device / Technology News | Medical Condition News
Tags: Antidepressant, Biomarker, Brain, Bupropion, Depression, Education, Lexapro, Mental Health, Neuroscience, Psychiatry, Serotonin, Wellbutrin
25. August 2009 23:36
The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to investigate whether patients with depression benefit from taking drugs belonging to the selective serotonin and norepinephrine reuptake inhibitor (SNRI) drug class.
[More]
24. August 2009 00:07
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
[More]
1. July 2009 21:56
The U.S. Food and Drug Administration has announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs.
[More] 
Subscribe